Will Organoids Fill the Gap towards Functional Precision Medicine?

Fecha de publicación: 21/11/2022 Fecha Ahead of Print: 21/11/2022

Autores de INCLIVA

Grupos y Plataformas de I+D+i

Grupo de Investigación en Cáncer Colorrectal y Nuevos Desarrollos Terapéuticos en Tumores Sólidos

Leading Researcher

Andrés Cervantes Ruiperez
Unidad de Medicina de Precisión

Abstract

Precision medicine approaches for solid tumors are mainly based on genomics. Its employment in clinical trials has led to somewhat underwhelming results, except for single responses. Moreover, several factors can influence the response, such as gene and protein expression, the coexistence of different genomic alterations or post-transcriptional/translational modifications, the impact of tumor microenvironment, etc., therefore making it insufficient to employ a genomics-only approach to predict response. Recently, the implementation of patient-derived organoids has shed light on the possibility to use them to predict patient response to drug treatment. This could offer for the first time the possibility to move precision medicine to a functional environment.

Datos de la publicación

ISSN/ISSNe:: 2075-4426, 2075-4426
Tipo:: Article
Páginas:: -
DOI:: 10.3390/jpm12111939
PubMed:: 36422115

Documentos

Published Version

Métricas

Filiaciones

Papaccio, Federica:: CIBER. Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Via S. Allende, 84081 Baronissi, Italy.; Biomedical Research Institute INCLIVA, Hospital Clinico Universitario, Department Medical Oncology, University of Valencia, 46010 Valencia, Spain.; Centro de Investigacion Biomedica en Red (CIBERONC), Instituto de Salud Carlos III, 28029 Madrid, Spain.; Department of Biochemistry and Molecular Biology, University of Valencia, 46010 Valencia, Spain

Instituto de Investigación. Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Via S. Allende, 84081 Baronissi, Italy.; Biomedical Research Institute INCLIVA, Hospital Clinico Universitario, Department Medical Oncology, University of Valencia, 46010 Valencia, Spain.; Centro de Investigacion Biomedica en Red (CIBERONC), Instituto de Salud Carlos III, 28029 Madrid, Spain.; Department of Biochemistry and Molecular Biology, University of Valencia, 46010 Valencia, Spain
Cabeza-Segura, Manuel:: Instituto de Investigación. Biomedical Research Institute INCLIVA, Hospital Clínico Universitario, Department Medical Oncology, University of Valencia, 46010 Valencia, Spain
Garcia-Mico, Blanca:: Instituto de Investigación. Biomedical Research Institute INCLIVA, Hospital Clínico Universitario, Department Medical Oncology, University of Valencia, 46010 Valencia, Spain
Tarazona, Noelia:: Instituto de Investigación. Biomedical Research Institute INCLIVA, Hospital Clínico Universitario, Department Medical Oncology, University of Valencia, 46010 Valencia, Spain

CIBER. Centro de Investigacion Biomedica en Red (CIBERONC), Instituto de Salud Carlos III, 28029 Madrid, Spain
Roda, Desamparados:: Instituto de Investigación. Biomedical Research Institute INCLIVA, Hospital Clínico Universitario, Department Medical Oncology, University of Valencia, 46010 Valencia, Spain

CIBER. Centro de Investigacion Biomedica en Red (CIBERONC), Instituto de Salud Carlos III, 28029 Madrid, Spain
Castillo, Josefa:: Instituto de Investigación. Biomedical Research Institute INCLIVA, Hospital Clínico Universitario, Department Medical Oncology, University of Valencia, 46010 Valencia, Spain

CIBER. Centro de Investigacion Biomedica en Red (CIBERONC), Instituto de Salud Carlos III, 28029 Madrid, Spain

Universidad. Department of Biochemistry and Molecular Biology, University of Valencia, 46010 Valencia, Spain
Cervantes, Andres:: Instituto de Investigación. Biomedical Research Institute INCLIVA, Hospital Clínico Universitario, Department Medical Oncology, University of Valencia, 46010 Valencia, Spain